Navigation Links
Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
Date:8/12/2011

PARSIPPANY, N.J., Aug. 12, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Wedbush Securities 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011, at 10:35 a.m. EDT being held at the Le Parker Meridien Hotel & Conference Center in New York City. Mr. Stack is expected to present an overview of the company.

A live audio webcast with accompanying slides of the Pacira presentation can be accessed by visiting the investors section of the company's website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.

About Pacira

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postsurgical analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.

Contacts:

James S. Scibetta
Chief Financial Officer
Pacira Pharmaceuticals, Inc.
(973) 254-3570

Jennifer Beugelmans
Vice President, Investor Relations
Pure Communications, Inc.
(646) 596-7473


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 , The data will be ... # 8006)   The conclusions of the study ... treated patients with 90% of the m presenting ... . Seventy two percent of the patients had clinical benefit. ... results from a Phase I study of plitidepsin in combination with bortezomib and ...
(Date:5/19/2016)... , May 19, 2016 ... titled, World Biopsy Devices Market Opportunities and Forecasts, ... devices market generated $1,621 million in 2015. The ... 2015, and is expected to maintain this trend ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... California State University Northridge ... quality of life and is currently focusing on ways to improve how people ... tested through research to find out whether watching them could have a significant ...
(Date:5/23/2016)... ... 2016 , ... During Logan University’s (Logan) Spring ... awarded $6,000 in chiropractic scholarships. The winners of the three $2,000 scholarships ... fifth trimester of classes at Logan. , “Standard Process has been extremely generous ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hospice of Westchester (HOW), ... for over 24 years, recently hosted its sixth annual Celebration of Life Memorial ... remembrance ceremonies, each concluding with the release of Monarch butterflies that honored the ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
(Date:5/23/2016)... ... May 23, 2016 , ... While new ... epidemic (1), physicians are not legally required to follow them. In the absence ... 3, 4). Novus Medical Detox Center , a leading Florida-based drug treatment ...
Breaking Medicine News(10 mins):